Author

V. A. Gushchin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Approach:deep learning· 1 Research Focus:differential expression· 1

Frequent Co-Authors

A. E. Siniavin· 3 shared A. A. Pochtovyi· 2 shared A. E. Sinyavin· 2 shared A. L. Gintsburg· 2 shared A. N. Zolotar· 2 shared D. A. Kleymenov· 2 shared E. N. Bykonia· 2 shared E. P. Mazunina· 2 shared

Activity by Year

2021-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

A. E. Siniavin

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Major role of S-glycoprotein in providing immunogenicity and protective immunity in mRNA lipid nanoparticle vaccines based on SARS-CoV-2 structural proteins

E. N. Bykonia, D. A. Kleymenov, V. A. Gushchin, A. E. Sinyavin, E. P. Mazunina, N. Kuznetsova, S. R. Kozlova, A. N. Zolotar, E. V. Shidlovskaya, E. V. Usachev, A. A. Pochtovyi, D. D. Kustova, I. A. Ivanov, S. E. Dmitriev, R. A. Ivanov, , A. L. Gintsburg

This study evaluates mRNA-LNP vaccines encoding SARS-CoV-2 structural proteins, finding that the S protein enhances immune responses to N protein, while M protein has low immunogenicity.

bioRxiv · Dec 30, 2023Immunology

Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response

E. P. Mazunina, V. A. Gushchin, D. A. Kleymenov, A. E. Sinyavin, E. I. Burtseva, M. M. Shmarov, E. A. Mukasheva, E. N. Bykonia, S. R. Kozlova, E. A. Evgrafova, A. N. Zolotar, E. V. Shidlovskaya, E. S. Kirillova, A. S. Krepkaia, E. V. Usachev, , A. L. Gintsburg

This study develops a trivalent mRNA vaccine candidate for seasonal flu, showing higher immunogenicity and cross-specific humoral immune response compared to an inactivated split vaccine.

bioRxiv · Dec 30, 2023Immunology

Lethality of West Nile virus strains in a mouse model

A. E. Siniavin, I. V. Dolzhikova, A. A. Pochtovyi, D. A. Reshetnikov, V. A. Gushchin

This study evaluates the lethality of different West Nile virus strains in a mouse model, highlighting the impact of amino acid substitutions on pathogenesis and vaccine development.

bioRxiv · Dec 22, 2023 · PreprintMicrobiology

SARS-CoV-2 cell-to-cell infection is resistant to neutralizing antibodies

N. Kruglova, A. E. Siniavin, V. A. Gushchin, D. Mazurov

This study quantifies SARS-CoV-2 cell-to-cell infection resistance to neutralizing antibodies, finding it is more than tenfold less susceptible than cell-free infection.

bioRxiv · May 4, 2021Microbiology

Snake venom phospholipases A2 possess a strong virucidal activity against SARS-CoV-2 in vitro and block the cell fusion mediated by spike glycoprotein interaction with the ACE2 receptor

A. E. Siniavin, M. A. Nikiforova, S. D. Grinkina, V. A. Gushchin, V. G. Starkov, A. V. Osipov, V. I. Tsetlin, Y. N. Utkin

This study shows that snake venom phospholipases A2, especially dimeric forms, have strong antiviral activity against SARS-CoV-2 by inactivating the virus and blocking cell fusion.

bioRxiv · Jan 12, 2021 · PreprintMicrobiology